Studying the effects of vitamin E and selenium for Alzheimer's disease prevention: The preadvise model

Allison M. Caban-Holt; Frederick A. Schmitt; C. R. Runyons; R. J. Kryscio; M. S. Mendiondo; M. S. Healey; W. R. Markesbery; C. A. Coltman; J. J. Crowley; P. J. Goodman; J. L. Hartline

Studying the effects of vitamin E and selenium for Alzheimer's disease prevention: The preadvise model

Allison M. Caban-Holt
, Frederick A. Schmitt
, C. R. Runyons
, R. J. Kryscio
, M. S. Mendiondo
, M. S. Healey
, W. R. Markesbery
, C. A. Coltman
, J. J. Crowley
, P. J. Goodman
, J. L. Hartline

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

5 Scopus citations

Abstract

Alzheimer's disease (AD) currently affects over 4 million Americans, and these numbers are expected to increase three-fold over the next 50 years. Worldwide prevalence is estimated to be between 18 and 34 million individuals. Though the etiologies of AD continue to remain elusive, the prevention of AD is becoming a critical focus for treatment. The PREADVISE study is investigating the long-term use of antioxidant supplements vitamin E and selenium for the prevention of AD. Further, PREADVISE is utilizing an innovative sub-study model in cooperation with the SELECT prostate cancer trial and has thus far accrued over 5,100 participants. This article introduces the PREADVISE/SELECT ancillary study model and discusses its potential benefits for conducting large-scale, longitudinal, clinical trials in dementia research.

Original language	English
Title of host publication	Research and Practice in Alzheimer's Disease
Editors	B. Vellas, E. Giacobini
Pages	124-130
Number of pages	7
State	Published - 2006

Publication series

Name	Research and Practice in Alzheimer's Disease
Volume	11
ISSN (Print)	1284-8360

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Alzheimer's disease
Antioxidants
Cognitive screening
PREADVISE
Prevention
SELECT
Study models

ASJC Scopus subject areas

Neuropsychology and Physiological Psychology
Aging
Geriatrics and Gerontology
Biological Psychiatry

Cite this

Caban-Holt, A. M., Schmitt, F. A., Runyons, C. R., Kryscio, R. J., Mendiondo, M. S., Healey, M. S., Markesbery, W. R., Coltman, C. A., Crowley, J. J., Goodman, P. J., & Hartline, J. L. (2006). Studying the effects of vitamin E and selenium for Alzheimer's disease prevention: The preadvise model. In B. Vellas, & E. Giacobini (Eds.), Research and Practice in Alzheimer's Disease (pp. 124-130). (Research and Practice in Alzheimer's Disease; Vol. 11).

@inbook{73530e8b0cb245ae8134cf15ddc14d51,

title = "Studying the effects of vitamin E and selenium for Alzheimer's disease prevention: The preadvise model",

abstract = "Alzheimer's disease (AD) currently affects over 4 million Americans, and these numbers are expected to increase three-fold over the next 50 years. Worldwide prevalence is estimated to be between 18 and 34 million individuals. Though the etiologies of AD continue to remain elusive, the prevention of AD is becoming a critical focus for treatment. The PREADVISE study is investigating the long-term use of antioxidant supplements vitamin E and selenium for the prevention of AD. Further, PREADVISE is utilizing an innovative sub-study model in cooperation with the SELECT prostate cancer trial and has thus far accrued over 5,100 participants. This article introduces the PREADVISE/SELECT ancillary study model and discusses its potential benefits for conducting large-scale, longitudinal, clinical trials in dementia research.",

keywords = "Alzheimer's disease, Antioxidants, Cognitive screening, PREADVISE, Prevention, SELECT, Study models",

author = "Caban-Holt, \{Allison M.\} and Schmitt, \{Frederick A.\} and Runyons, \{C. R.\} and Kryscio, \{R. J.\} and Mendiondo, \{M. S.\} and Healey, \{M. S.\} and Markesbery, \{W. R.\} and Coltman, \{C. A.\} and Crowley, \{J. J.\} and Goodman, \{P. J.\} and Hartline, \{J. L.\}",

year = "2006",

language = "English",

isbn = "2914377959",

series = "Research and Practice in Alzheimer's Disease",

pages = "124--130",

editor = "B. Vellas and E. Giacobini",

booktitle = "Research and Practice in Alzheimer's Disease",

}

Caban-Holt, AM, Schmitt, FA, Runyons, CR, Kryscio, RJ, Mendiondo, MS, Healey, MS, Markesbery, WR, Coltman, CA, Crowley, JJ, Goodman, PJ & Hartline, JL 2006, Studying the effects of vitamin E and selenium for Alzheimer's disease prevention: The preadvise model. in B Vellas & E Giacobini (eds), Research and Practice in Alzheimer's Disease. Research and Practice in Alzheimer's Disease, vol. 11, pp. 124-130.

Studying the effects of vitamin E and selenium for Alzheimer's disease prevention: The preadvise model. / Caban-Holt, Allison M.; Schmitt, Frederick A.; Runyons, C. R. et al.
Research and Practice in Alzheimer's Disease. ed. / B. Vellas; E. Giacobini. 2006. p. 124-130 (Research and Practice in Alzheimer's Disease; Vol. 11).

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

TY - CHAP

T1 - Studying the effects of vitamin E and selenium for Alzheimer's disease prevention

T2 - The preadvise model

AU - Caban-Holt, Allison M.

AU - Schmitt, Frederick A.

AU - Runyons, C. R.

AU - Kryscio, R. J.

AU - Mendiondo, M. S.

AU - Healey, M. S.

AU - Markesbery, W. R.

AU - Coltman, C. A.

AU - Crowley, J. J.

AU - Goodman, P. J.

AU - Hartline, J. L.

PY - 2006

Y1 - 2006

N2 - Alzheimer's disease (AD) currently affects over 4 million Americans, and these numbers are expected to increase three-fold over the next 50 years. Worldwide prevalence is estimated to be between 18 and 34 million individuals. Though the etiologies of AD continue to remain elusive, the prevention of AD is becoming a critical focus for treatment. The PREADVISE study is investigating the long-term use of antioxidant supplements vitamin E and selenium for the prevention of AD. Further, PREADVISE is utilizing an innovative sub-study model in cooperation with the SELECT prostate cancer trial and has thus far accrued over 5,100 participants. This article introduces the PREADVISE/SELECT ancillary study model and discusses its potential benefits for conducting large-scale, longitudinal, clinical trials in dementia research.

AB - Alzheimer's disease (AD) currently affects over 4 million Americans, and these numbers are expected to increase three-fold over the next 50 years. Worldwide prevalence is estimated to be between 18 and 34 million individuals. Though the etiologies of AD continue to remain elusive, the prevention of AD is becoming a critical focus for treatment. The PREADVISE study is investigating the long-term use of antioxidant supplements vitamin E and selenium for the prevention of AD. Further, PREADVISE is utilizing an innovative sub-study model in cooperation with the SELECT prostate cancer trial and has thus far accrued over 5,100 participants. This article introduces the PREADVISE/SELECT ancillary study model and discusses its potential benefits for conducting large-scale, longitudinal, clinical trials in dementia research.

KW - Alzheimer's disease

KW - Antioxidants

KW - Cognitive screening

KW - PREADVISE

KW - Prevention

KW - SELECT

KW - Study models

UR - https://www.scopus.com/pages/publications/33847040744

UR - https://www.scopus.com/pages/publications/33847040744#tab=citedBy

M3 - Chapter

AN - SCOPUS:33847040744

SN - 2914377959

SN - 9782914377959

T3 - Research and Practice in Alzheimer's Disease

SP - 124

EP - 130

BT - Research and Practice in Alzheimer's Disease

A2 - Vellas, B.

A2 - Giacobini, E.

ER -

Studying the effects of vitamin E and selenium for Alzheimer's disease prevention: The preadvise model

Abstract

Publication series

UN SDGs

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this